No Data
This DB Chart Shows How the Tech Selloff Is Driving Moves Throughout the Stock Market
Novo Nordisk Shares Decline Amid Competitive Pressure
Smart Money Is Betting Big In MRK Options
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
we've reached a top.
FChoyDG : Good read
Lucky2828 : Although they are the biggest ETF fund but they are still not the controller in US market.